Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Globus Medical Inc (NYSE: GMED) was $62.79 for the day, up 1.49% from the previous closing price of $61.87. In other words, the price has increased by $1.49 from its previous closing price. On the day, 1.56 million shares were traded. GMED stock price reached its highest trading level at $63.11 during the session, while it also had its lowest trading level at $61.695.
Ratios:
Our analysis of GMED’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 36.96 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.08. For the most recent quarter (mrq), Quick Ratio is recorded 2.26 and its Current Ratio is at 4.07. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
On January 10, 2025, BofA Securities Upgraded its rating to Neutral which previously was Underperform but kept the price unchanged to $97.
Morgan Stanley Upgraded its Equal-Weight to Overweight on December 02, 2024, whereas the target price for the stock was revised from $83 to $100.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 28 ’25 when RHOADS ANN D sold 7,500 shares for $78.68 per share. The transaction valued at 590,100 led to the insider holds 35,384 shares of the business.
RHOADS ANN D bought 7,500 shares of GMED for $590,000 on Feb 28 ’25. On Jan 10 ’25, another insider, Pfeil Keith W, who serves as the COO, CFO of the company, sold 14,167 shares for $88.29 each. As a result, the insider received 1,250,770 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMED now has a Market Capitalization of 8480228864 and an Enterprise Value of 8247954944. As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 24.23, and their Forward P/E ratio for the next fiscal year is 17.14. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.56. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.23 while its Price-to-Book (P/B) ratio in mrq is 1.97. Its current Enterprise Value per Revenue stands at 3.14 whereas that against EBITDA is 11.214.
Stock Price History:
The Beta on a monthly basis for GMED is 1.17, which has changed by -0.08722198 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, GMED has reached a high of $94.93, while it has fallen to a 52-week low of $51.79. The 50-Day Moving Average of the stock is 9.66%, while the 200-Day Moving Average is calculated to be -13.58%.
Shares Statistics:
GMED traded an average of 1.54M shares per day over the past three months and 1781870 shares per day over the past ten days. A total of 112.62M shares are outstanding, with a floating share count of 111.82M. Insiders hold about 17.20% of the company’s shares, while institutions hold 83.68% stake in the company. Shares short for GMED as of 1753920000 were 4783494 with a Short Ratio of 3.11, compared to 1751241600 on 4312022. Therefore, it implies a Short% of Shares Outstanding of 4783494 and a Short% of Float of 4.760000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A comprehensive evaluation of Globus Medical Inc (GMED) is underway, with the input of 13.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.89, with high estimates of $0.95 and low estimates of $0.72.
Analysts are recommending an EPS of between $3.35 and $3.15 for the fiscal current year, implying an average EPS of $3.22. EPS for the following year is $3.61, with 14.0 analysts recommending between $4.15 and $3.01.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 10 analysts. It ranges from a high estimate of $747.02M to a low estimate of $728M. As of the current estimate, Globus Medical Inc’s year-ago sales were $625.71MFor the next quarter, 10 analysts are estimating revenue of $778.03M. There is a high estimate of $797.9M for the next quarter, whereas the lowest estimate is $760.58M.
A total of 12 analysts have provided revenue estimates for GMED’s current fiscal year. The highest revenue estimate was $2.89B, while the lowest revenue estimate was $2.84B, resulting in an average revenue estimate of $2.86B. In the same quarter a year ago, actual revenue was $2.52BBased on 12 analysts’ estimates, the company’s revenue will be $3.08B in the next fiscal year. The high estimate is $3.14B and the low estimate is $3B.
